A qualitative treatment for osteoarthritis in Syria and a patent in pharmaceutical form!

Joint pain is one of the diseases that many suffer from, and studies indicate that one in 5 people over forty-five years of age suffers from osteoarthritis symptoms, which is damage to the joint cartilage tissue that reduces friction resulting from joint movement. Permanent. Osteoarthritis is one of the most important reasons for determining movement, hence the importance of concerted efforts of experts in search of quality and advanced treatments to treat this disease and reduce its effects.

In this context, MAM International sought to provide the best quality treatment options in this field, as MAM International recently launched a new drug in the Syrian market called Mucosat® as a revolutionary and patented treatment in a pharmaceutical form that helps to recover from osteoarthritis, protect cartilage, and treat pain in the spine and joints in a form. Year.

Training activities for a group of medical representatives of MAM International were held in Damascus on the twenty first of last September, and the composition of the drug Mucosat®, which is chondroitin sulfate intended for intramuscular and intra-articular injection, was introduced as an effective drug for the treatment of degenerative diseases of the limbs and joints of the spine, which can be Its anti-inflammatory and analgesic effects of chondroprotectors can help improve mobility and delay the exacerbation of osteoarthritis. Mucosat® also plays an important role in the restoration of cartilage and tendons, and supporting the structural integrity of tissues.

Leave a Reply

Your email address will not be published.